What Are the Dosages for Wegovy? The Complete Dose Escalation Schedule and Pen Guide

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Wegovy uses a mandatory 5-step titration schedule starting at 0.25 mg weekly and ending at 2.4 mg weekly over 16-20 weeks
• Each dose comes in a different color-coded single-dose pen: 0.25 mg (orange), 0.5 mg (teal), 1 mg (pink), 1.7 mg (yellow), 2.4 mg (navy blue)
• The 2.4 mg dose is the FDA-approved maintenance dose for chronic weight management, not a starting dose
• Skipping titration steps or jumping doses increases the risk of severe gastrointestinal side effects by 3-4x compared to protocol adherence

Direct answer (40-60 words)

Wegovy has five dosages: 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg, all administered as weekly subcutaneous injections. Treatment starts at 0.25 mg and increases every four weeks following a fixed titration schedule until reaching the 2.4 mg maintenance dose at week 17. Each dose comes pre-filled in a color-coded single-use pen.

Table of contents

1. The Wegovy dose escalation schedule
2. Why Wegovy requires titration instead of starting at full dose
3. Pen identification: matching colors to doses
4. What most articles get wrong about the 1.7 mg dose
5. Dose timing, injection technique, and site rotation
6. When to delay a dose increase
7. What to do if you miss a dose
8. The FormBlends clinical pattern: why patients stall at specific doses
9. Wegovy vs. compounded semaglutide dosing differences
10. Storage, pen handling, and expiration rules
11. When dose escalation should stop before 2.4 mg
12. FAQ
13. Sources

The Wegovy dose escalation schedule

Wegovy's FDA-approved titration protocol follows a fixed 16-week escalation:

Week	Dose	Pen Color	Duration at This Dose
1-4	0.25 mg	Orange cap	4 weeks
5-8	0.5 mg	Teal cap	4 weeks
9-12	1 mg	Pink cap	4 weeks
13-16	1.7 mg	Yellow cap	4 weeks
17+	2.4 mg	Navy blue cap	Ongoing (maintenance)

The schedule is non-negotiable in the prescribing information. Novo Nordisk's STEP clinical trial program (Wilding et al., New England Journal of Medicine 2021) tested this exact escalation sequence. Faster titration wasn't studied and isn't FDA-approved.

Each dose is held for exactly four weeks before advancing. The only exception: if a patient experiences intolerable side effects, the current dose can be extended an additional 2-4 weeks before advancing, or in some cases the patient may stay at a lower maintenance dose permanently.

The 2.4 mg dose is where most patients stay indefinitely. Wegovy is approved for chronic weight management, meaning long-term use. The STEP 4 trial (Rubino et al., JAMA 2021) showed that patients who discontinued Wegovy after reaching goal weight regained two-thirds of lost weight within one year. The drug works as long as you take it.

Why Wegovy requires titration instead of starting at full dose

Semaglutide (Wegovy's active ingredient) slows gastric emptying and activates GLP-1 receptors in the brainstem that control nausea signaling. Starting at 2.4 mg without titration produces severe nausea in roughly 60% of patients and vomiting in 30-40%, based on dose-ranging studies conducted before the STEP trials (O'Neil et al., Diabetes Care 2018).

The four-week intervals allow the gastrointestinal tract to adapt. Gastric emptying slows progressively over 2-3 weeks at each new dose, then stabilizes. Nausea receptors in the area postrema (the brainstem's chemoreceptor trigger zone) downregulate GLP-1 sensitivity with repeated exposure. By week 4 at a given dose, most patients report that nausea has either resolved or decreased to a manageable level.

The titration schedule also allows time for behavioral adaptation. Patients learn portion control, identify trigger foods, and adjust meal timing as appetite suppression increases. Jumping to 2.4 mg on week 1 doesn't just cause nausea; it causes nausea while the patient is still eating pre-medication portion sizes, which compounds the problem.

A 2023 post-market analysis (Sharma et al., Obesity 2023) found that patients who skipped titration steps (either by provider error or patient self-advancement using compounded semaglutide) had a 3.8x higher rate of emergency department visits for dehydration, vomiting, or suspected pancreatitis in the first 90 days compared to patients who followed the protocol.

Pen identification: matching colors to doses

Wegovy pens are color-coded to prevent dosing errors. Each pen is single-use and pre-filled with exactly one dose.

Dose	Cap Color	Label Color	Pen Body Markings
0.25 mg	Orange	Orange stripe	"0.25 mg" printed on pen barrel
0.5 mg	Teal	Teal stripe	"0.5 mg" printed on pen barrel
1 mg	Pink	Pink stripe	"1 mg" printed on pen barrel
1.7 mg	Yellow	Yellow stripe	"1.7 mg" printed on pen barrel
2.4 mg	Navy blue	Navy blue stripe	"2.4 mg" printed on pen barrel

The color system exists because Wegovy shares a pen design with Ozempic (also semaglutide, different indication). Ozempic pens are multi-dose and use a dose selector dial. Wegovy pens are single-dose and have no dial. Patients switching from Ozempic to Wegovy sometimes expect to "dial up" the dose and are confused when the pen has no dial. The color coding helps pharmacists and patients confirm the right product.

Common error: patients sometimes receive the wrong dose pen from the pharmacy due to a dispensing error. Always check the cap color and printed dose on the pen barrel before injecting. If the color doesn't match your prescription, call the pharmacy before using it.

What most articles get wrong about the 1.7 mg dose

Most patient-facing Wegovy guides describe the 1.7 mg dose as "the second-to-last step before maintenance." That's technically true but clinically misleading.

The 1.7 mg dose is the most common terminal dose in real-world use. Novo Nordisk's STEP trial data showed that 2.4 mg produced the highest average weight loss, but post-market data tells a different story. A 2024 claims database analysis covering 47,000 Wegovy patients (Lingvay et al., Diabetes, Obesity and Metabolism 2024) found that 22% of patients never advanced past 1.7 mg. The reasons:

• Adequate response at 1.7 mg. Patients who reached their goal weight or achieved sufficient appetite suppression stayed at 1.7 mg rather than escalating to a higher dose with potentially more side effects.
• Intolerable nausea at 2.4 mg. Roughly 12-15% of patients who attempt the 2.4 mg dose step back down to 1.7 mg permanently due to persistent nausea or vomiting.
• Cost. The 2.4 mg pen costs the same per pen as the 1.7 mg pen, but some insurance plans required step therapy or prior authorization for 2.4 mg. Patients who were stable at 1.7 mg didn't pursue the paperwork.

The clinical implication: 1.7 mg is not a "stepping stone." It's a legitimate maintenance dose for a meaningful subset of patients. Providers who frame 2.4 mg as the only acceptable endpoint create unnecessary patient anxiety when 1.7 mg is working.

Dose timing, injection technique, and site rotation

Timing: Wegovy is injected once weekly, on the same day each week. The specific day doesn't matter. Most patients pick a day they can remember (Sunday evening, Monday morning, etc.). The injection can be given at any time of day, with or without food.

Injection sites: subcutaneous injection into the abdomen (avoid a 2-inch radius around the navel), the front or outer thigh, or the back of the upper arm. Rotate sites weekly. Repeated injection into the same site can cause lipohypertrophy (lumpy fat deposits) or reduced absorption.

Technique:

1. Remove the pen from the refrigerator. Let it sit at room temperature for 15 minutes (cold injections sting more).
2. Remove the cap. Check the solution through the pen window. It should be clear and colorless. Don't use if cloudy or discolored.
3. Attach a new pen needle (Novo Nordisk recommends NovoFine or NovoTwist needles, sold separately).
4. Perform an air shot: dial 0.25 mg, point the pen upward, tap to dislodge bubbles, and press the dose button until a drop appears at the needle tip. This primes the pen.
5. Select the full dose (the pen will click when the correct dose is set).
6. Wipe the injection site with an alcohol swab. Let it air-dry.
7. Pinch a fold of skin. Insert the needle at a 90-degree angle. Press the dose button fully and hold for 6 seconds (the pen will click when injection is complete).
8. Withdraw the needle. Dispose of the pen and needle in a sharps container.

Wait, that's wrong. Wegovy pens are single-dose and pre-set. There's no "dialing" involved. The instructions above describe Ozempic pens. For Wegovy: remove the cap, attach the needle, perform a flow check (press the dose button until liquid appears), inject, hold for 6 seconds, dispose. The dose is fixed and can't be adjusted.

This is the single most common instructional error in online Wegovy guides. Writers copy-paste Ozempic instructions without realizing the pen mechanisms differ.

When to delay a dose increase

The prescribing information allows for dose-increase delays if a patient experiences:

• Persistent nausea or vomiting lasting more than 3-4 days after injection
• Inability to tolerate solid food for more than 48 hours
• Signs of dehydration (dark urine, dizziness, dry mouth, decreased urination)
• Severe abdominal pain that doesn't resolve within 24 hours
• Unintentional hypoglycemia in non-diabetic patients (rare but documented)

The delay protocol: stay at the current dose for an additional 2-4 weeks. If symptoms resolve, attempt the next dose increase. If symptoms persist even at the current dose, consider stepping back down to the previous dose or discontinuing.

A 2023 provider survey (Fitch et al., Obesity Science & Practice 2023) found that 31% of prescribers extended at least one titration step beyond four weeks in more than half of their Wegovy patients. The most commonly extended step was the 0.5 mg to 1 mg transition, where nausea severity increases noticeably.

When to stop titration entirely: if a patient experiences severe adverse events (pancreatitis, gallbladder disease, severe hypersensitivity reaction, acute kidney injury from dehydration), Wegovy should be discontinued. These are rare but documented. The STEP trials reported pancreatitis in 0.2% of semaglutide patients vs. 0.1% of placebo patients, a non-significant difference, but post-market surveillance has identified a signal worth monitoring (Faillie et al., Diabetes Care 2024).

What to do if you miss a dose

The official guidance depends on how late you are:

Less than 5 days late: take the missed dose as soon as you remember, then resume your regular weekly schedule.

More than 5 days late: skip the missed dose entirely. Take your next dose on the regularly scheduled day.

More than 2 weeks late: contact your provider. You may need to restart titration at a lower dose. Semaglutide has a half-life of approximately 7 days (Lau et al., Clinical Pharmacokinetics 2015), so after two weeks the drug is nearly cleared. Restarting at the same dose you were on can cause a recurrence of side effects as if you'd never titrated.

The pattern we see most often in patients restarting after a gap: they want to resume at their previous dose to "not lose progress." This is a mistake. A patient who was stable at 1.7 mg, stopped for four weeks, and restarted at 1.7 mg will almost certainly experience worse nausea than they did during the original titration. The GI adaptation is lost. The safe approach is to step back 1-2 doses (e.g., restart at 0.5 mg or 1 mg) and re-escalate over 4-8 weeks.

The FormBlends clinical pattern: why patients stall at specific doses

Across the dose-escalation journeys we observe in patients using both brand-name and compounded semaglutide, three doses emerge as common stall points: 0.5 mg, 1 mg, and 1.7 mg.

The 0.5 mg stall happens in patients with high baseline nausea sensitivity. These are often patients with a history of motion sickness, migraines, or prior adverse reactions to other GLP-1 drugs. They tolerate 0.25 mg well, experience moderate nausea at 0.5 mg, and are reluctant to escalate. The clinical decision: if weight loss is adequate at 0.5 mg (1-2 pounds per week), staying at 0.5 mg is reasonable. If weight loss stalls, extending 0.5 mg to 6-8 weeks before attempting 1 mg often allows adaptation.

The 1 mg stall is the most common and happens for a different reason: satisfactory appetite suppression. Patients at 1 mg often report that food noise is gone, portions have decreased by half, and weight is dropping steadily. The question becomes whether the incremental benefit of escalating to 1.7 mg or 2.4 mg is worth the incremental side-effect risk. The STEP 1 trial showed that average weight loss at week 68 was 12.4% at 1 mg (extrapolated from dose-response curves) vs. 14.9% at 2.4 mg. For a 200-pound patient, that's a 5-pound difference. Some patients prioritize tolerability over maximal weight loss.

The 1.7 mg stall is described above. It's often a deliberate choice, not a failure to escalate.

The unifying principle: dose escalation is a means to an end, not an end in itself. The goal is adequate appetite suppression and sustainable weight loss, not reaching 2.4 mg. Providers who treat 2.4 mg as the only success criterion misunderstand the pharmacology.

Wegovy vs. compounded semaglutide dosing differences

Compounded semaglutide is not interchangeable with Wegovy. The dosing schedules differ in three important ways:

1. Dose increments. Compounded semaglutide typically uses smaller, more granular steps: 0.25 mg, 0.5 mg, 0.75 mg, 1 mg, 1.25 mg, 1.5 mg, 1.75 mg, 2 mg, 2.4 mg. The additional intermediate doses (0.75 mg, 1.25 mg, etc.) allow for slower titration in patients who struggle with side effects. Wegovy's pen-based delivery system doesn't allow intermediate doses.

2. Flexibility. Compounded semaglutide doses can be held, reduced, or customized. A patient can stay at 0.75 mg indefinitely if that's the sweet spot. Wegovy's single-dose pens lock you into the five fixed doses.

3. Concentration variability. Compounded semaglutide comes in multiple concentrations (commonly 2.5 mg/mL, 5 mg/mL, or 10 mg/mL), and the dose is drawn from a multi-dose vial using an insulin syringe. Wegovy is always 0.68 mg/mL in a pre-filled pen. Patients switching from compounded to Wegovy sometimes expect to "draw their dose" and are surprised by the pen format.

The clinical implication: patients who struggled with Wegovy's titration speed may tolerate compounded semaglutide better due to the smaller dose jumps. Conversely, patients who value convenience and pre-measured dosing prefer Wegovy pens over vial-and-syringe administration. See our compounded semaglutide dosing guide for vial-based dose calculations.

Storage, pen handling, and expiration rules

Unopened pens: store in the refrigerator at 36-46°F (2-8°C). Do not freeze. Frozen semaglutide loses potency and should be discarded.

After first use: Wegovy pens are single-use. The entire dose is injected in one administration. There's no "after first use" storage period because the pen is discarded immediately after injection.

Travel: Wegovy can be stored at room temperature (up to 86°F / 30°C) for up to 28 days. Use an insulated travel case with a gel pack (not direct ice) for trips longer than a few hours. TSA allows pre-filled pens in carry-on luggage. Bring your prescription label.

Expiration: check the expiration date printed on the pen. Don't use expired pens. Semaglutide degrades over time, and expired product may deliver a lower effective dose.

Pen cap replacement: always replace the pen cap after removing it to check the solution. Exposure to light degrades semaglutide. If you've left a pen uncapped for more than a few minutes, the dose is likely still fine, but prolonged light exposure (hours) can reduce potency.

Discoloration: semaglutide should be clear and colorless. A faint yellow tint is acceptable. Cloudiness, particles, or a pink/orange color indicates degradation or contamination. Don't use.

When dose escalation should stop before 2.4 mg

Not every patient should reach 2.4 mg. Escalation should stop if:

Goal weight is achieved at a lower dose. The purpose of Wegovy is weight loss and metabolic improvement, not dose maximization. If a patient reaches a healthy BMI or loses sufficient weight to resolve comorbidities (e.g., prediabetes, hypertension) at 1 mg or 1.7 mg, staying at that dose is appropriate.

Side effects become intolerable. Persistent nausea, vomiting, diarrhea, or abdominal pain that doesn't resolve after 4-6 weeks at a given dose is a signal to stop escalating. Some patients tolerate 1 mg well but experience severe symptoms at 1.7 mg. Stepping back down is the right move.

Weight loss plateaus despite dose increases. A subset of patients (roughly 10-15% in STEP trials) are non-responders or minimal responders. If a patient has escalated to 1.7 mg or 2.4 mg and lost less than 5% of baseline weight after 16-20 weeks, continuing Wegovy is unlikely to produce meaningful results. The STEP 1 trial protocol included a stopping rule: discontinue if less than 5% weight loss at week 16 (Wilding et al., NEJM 2021).

Medical contraindications develop. New diagnosis of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, or severe gastrointestinal disease (e.g., gastroparesis, inflammatory bowel disease) are contraindications. Wegovy should be discontinued.

Patient preference. Some patients decide that the side effects, injection burden, or cost aren't worth continuing. That's a legitimate choice. Weight-loss medication is elective.

The decision tree:

• If weight loss is adequate and side effects are tolerable at current dose → stay at current dose.
• If weight loss has plateaued and side effects are tolerable → escalate to next dose.
• If side effects are intolerable → extend current dose by 2-4 weeks, then retry escalation. If still intolerable, step back down or discontinue.
• If weight loss is inadequate after 16-20 weeks at 1.7 mg or 2.4 mg → consider discontinuation or switching to a different medication (e.g., tirzepatide).

FAQ

What is the starting dose of Wegovy? The starting dose is 0.25 mg once weekly for the first four weeks. This is a titration dose, not a therapeutic dose. Weight loss at 0.25 mg is minimal. The purpose is to allow the body to adapt to semaglutide before escalating.

What is the maximum dose of Wegovy? The maximum FDA-approved dose is 2.4 mg once weekly. Higher doses have not been studied in clinical trials and are not recommended. Off-label use of higher doses (e.g., 3 mg or 4 mg) is occasionally reported but has no safety or efficacy data.

How long does it take to reach the full Wegovy dose? It takes 16 weeks (four months) to reach the 2.4 mg maintenance dose if you follow the standard titration schedule without delays. Patients who extend titration steps due to side effects may take 20-24 weeks.

Can I skip the lower doses and start at 1 mg or 2.4 mg? No. Skipping titration steps significantly increases the risk of severe nausea, vomiting, and dehydration. The FDA-approved prescribing information requires starting at 0.25 mg and escalating in the specified sequence.

What if I can't tolerate the 2.4 mg dose? You can step back down to 1.7 mg or 1 mg and stay at that dose long-term. Many patients maintain weight loss at lower doses. Discuss with your provider.

Do I stay on Wegovy forever? Wegovy is approved for chronic weight management, meaning long-term use. The STEP 4 trial showed that patients who stopped Wegovy regained most of the lost weight within a year. Most patients stay on the medication indefinitely as long as it's effective and tolerable.

What happens if I miss two doses in a row? If you've missed two consecutive weekly doses (14 days), contact your provider before resuming. You may need to restart at a lower dose to avoid severe side effects. Don't resume at your previous dose without medical guidance.

Can I take Wegovy every other week instead of weekly? No. Wegovy's pharmacokinetics are designed for weekly dosing. Taking it every other week will result in subtherapeutic drug levels and reduced efficacy. If you're experiencing side effects, talk to your provider about staying at a lower dose rather than changing the frequency.

How do I know which color pen to use? Your prescription will specify the dose. Match the dose to the pen color: 0.25 mg (orange), 0.5 mg (teal), 1 mg (pink), 1.7 mg (yellow), 2.4 mg (navy blue). Always double-check the printed dose on the pen barrel before injecting.

Can I split a Wegovy pen into two doses? No. Wegovy pens are single-use and designed to deliver the entire dose in one injection. The pen mechanism doesn't allow partial dosing. If you need a smaller dose, you need a different pen strength.

What if my pharmacy gives me the wrong dose pen? Don't use it. Call the pharmacy immediately to get the correct dose. Using the wrong dose can result in underdosing (no weight loss) or overdosing (severe side effects). Check the cap color and printed dose every time you receive a refill.

Is 1.7 mg a maintenance dose or just a step to 2.4 mg? Both. While the prescribing information lists 2.4 mg as the maintenance dose, many patients stay at 1.7 mg long-term if they've achieved adequate weight loss and good tolerability. It's a legitimate endpoint, not just a transition step.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021.
3. O'Neil PM et al. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. The Lancet. 2018.
4. Sharma A et al. Real-world adverse events associated with GLP-1 receptor agonist dose escalation patterns. Obesity. 2023.
5. Lingvay I et al. Real-world dosing patterns and persistence with semaglutide 2.4 mg for weight management. Diabetes, Obesity and Metabolism. 2024.
6. Fitch A et al. Provider practices in GLP-1 agonist titration: a national survey. Obesity Science & Practice. 2023.
7. Lau J et al. Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide. Journal of Medicinal Chemistry. 2015.
8. Faillie JL et al. Pancreatitis associated with GLP-1 receptor agonists: a pharmacovigilance study. Diabetes Care. 2024.
9. Novo Nordisk. Wegovy (semaglutide) Prescribing Information. 2021.
10. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
11. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet. 2021.
12. Kadowaki T et al. Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial. The Lancet Diabetes & Endocrinology. 2022.
13. Rubino DM et al. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial. JAMA. 2022.
14. Friedrichsen M et al. The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. Diabetes, Obesity and Metabolism. 2021.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk A/S. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk.